Drugs & Aging

, Volume 17, Issue 3, pp 217–227

Pharmacoeconomics of Influenza Vaccination in the Elderly

Reviewing the Available Evidence
  • Maarten J. Postma
  • Rob M. P. M. Baltussen
  • Marie-Louise A. Heijnen
  • Lolkje T. W. de Jong-van den Berg
  • Johannes C. Jager
Review Article

Abstract

Most western countries have influenza vaccination programmes for citizens aged ≥65 years. This paper reviews the available evidence on whether elderly influenza vaccination is worthwhile from a pharmacoeconomic point of view.

A search on Medline and EMBASE resulted in a primary selection of approximately 100 studies on the pharmacoeconomics of influenza vaccination in the elderly. Further selection of studies to be included in the review was based on several criteria such as original research paper, cost-benefit or cost-effectiveness analysis, influenza vaccination in the elderly, and publication between 1980 and 1999.

The 10 studies included in the final selection were evaluated regarding 3 main aspects: benefit-cost ratio and cost-effectiveness ratio; vaccine effectiveness; and relative costing of the vaccine.

In general, differences in benefit-cost ratios could be explained by differences in effectiveness and relative costing of the vaccine. Considering the available pharmacoeconomic evidence, influenza vaccination of the elderly in western countries is an intervention with favourable cost-effectiveness in terms of net costs per life-year gained and even has cost-saving potential.

In particular, influenza vaccination among elderly people at higher risk, such as the chronically ill elderly, is generally found to be cost saving. Relatively favourable cost-effectiveness among non-high-risk elderly justifies universal influenza vaccination of the elderly from a pharmacoeconomic point of view.

References

  1. 1.
    Sullivan MS, Monto AS, Longini IM. Estimates of the US health impact of influenza. Am J Public Health 1993; 12: 1712–6CrossRefGoogle Scholar
  2. 2.
    Centers for Disease Control. Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 1998; 47(R6): 1–26Google Scholar
  3. 3.
    Ambrosch F, Fedson DS. Influenza vaccination in 29 countries: an update to 1997. Pharmacoeconomics 1999; 16Suppl. 1: 47–54PubMedCrossRefGoogle Scholar
  4. 4.
    Snacken R, Szucs TD, editors. The socioeconomics of influenza and its control measures. Pharmacoeconomics 1999; 16Suppl. 1: 1–100Google Scholar
  5. 5.
    Hannoun C, editor. The socioeconomics of influenza and influenza vaccination in Europe. Pharmacoeconomics 1996; 9Suppl. 3: 1–81Google Scholar
  6. 6.
    Schoenbaum SC, McNeil BJ, Kavet J. The swine-influenza decision. N Engl J Med 1976; 295: 759–65PubMedCrossRefGoogle Scholar
  7. 7.
    Kavet J. A perspective on the significance of pandemic influenza. Am J Public Health 1977; 67: 1063–70PubMedCrossRefGoogle Scholar
  8. 8.
    Smith JWG, Pollard R. Vaccination against influenza: a five-year study in the Post Office. J Hyg (Lond) 1979; 83: 157–80CrossRefGoogle Scholar
  9. 9.
    Fedson DS. Evaluating the impact of influenza vaccination: a North American perspective. Pharmacoeconomics 1996; 9Suppl. 3: 54–61PubMedCrossRefGoogle Scholar
  10. 10.
    Sisk JE, Moskowitz AT, Whang W et al. Cost-effectiveness of vaccination against pneumococcal bacteremia among elderly people. JAMA 1997; 16: 1333–9CrossRefGoogle Scholar
  11. 11.
    Fine PEM. The contribution of modelling to vaccination policy. In: Cutts FT, Smith PG, editors. Vaccination and world health. Chichester: John Wiley & Sons Ltd, 1994: 177–92Google Scholar
  12. 12.
    Holtgrave DR, editor. Handbook of economic evaluation of HIV prevention programmes. New York: Plenum Press, 1998Google Scholar
  13. 13.
    Postma MJ, Weite R, van den Hoek JAR, et al. Opportunistic screening for genital infections with Chlamydia trachomutis among the sexually active population of Amsterdam: II. Cost effectiveness analysis of screening women [in Dutch]. Nederlands Tijdschrift voor Geneeskunde 1999; 143: 677–81PubMedGoogle Scholar
  14. 14.
    Postma MJ, Beck EJ, Mandalia S, et al. Universal HIV screening of pregnant women in England: cost effectiveness analysis. BMJ 1999; 318: 1656–60PubMedCrossRefGoogle Scholar
  15. 15.
    Drummond MF, O’Brien BJ, Stoddart GL, et al. Methods for the economic evaluation of health care programmes. Oxford: Oxford University Press, 1997Google Scholar
  16. 16.
    McBean AM, Babish D, Warren JL. The impact and cost of influenza in the elderly. Arch Intern Med 1993; 153: 2105–11PubMedCrossRefGoogle Scholar
  17. 17.
    Evans DB, Hensley MJ, O’Connor SJ. Influenza vaccination in Australia: a review of the economic evidence for policy recommendations. Med J Aust 1988; 149: 540–3PubMedGoogle Scholar
  18. 18.
    Campbell DS, Rumley MH. Cost-effectiveness of the influenza vaccine in a healthy, working-age population. J Occup Environ Med 1997; 39: 408–14PubMedCrossRefGoogle Scholar
  19. 19.
    Riddiough MA, Sisk JE, Bell JC. Influenza vaccination: cost-effectiveness and public policy. JAMA 1983; 249: 3189–95PubMedCrossRefGoogle Scholar
  20. 20.
    Patriarca PA, Arden NH, Koplan JP, et al. Prevention and control of type A influenza infections in nrsing homes: benefits and costs of four approaches using vaccination and amantadme. Ann Intern Med 1987; 107: 732–40PubMedGoogle Scholar
  21. 21.
    Helliwell BE, Drummond MF. The costs and benefits of preventing influenza in Ontario’s elderly. Can J Publ Health 1988; 79: 175–80Google Scholar
  22. 22.
    Maucher JM, Gambert SM. Cost-effective analysis of influenza vaccination in the elderly. Age 1990; 13: 81–5CrossRefGoogle Scholar
  23. 23.
    Grabenstein JD, Hartzema AG, Guess HA, et al. Community pharmacists as immunization advocates: cost-effectiveness of a cue to influenza vaccination. Med Care 1992; 30: 503–13PubMedCrossRefGoogle Scholar
  24. 24.
    Mullooly JP, Bennett MD, Hornbrook MC, et al. Influenza vaccination programs for elderly persons: cost effectiveness in a health maintenance organization. Ann Intern Med 1994; 121: 947–52PubMedGoogle Scholar
  25. 25.
    Scott WG, Scott HM. Economic evaluation of vaccination against influenza in New Zealand. Pharmacoeconomics 1996; 9:51–60PubMedCrossRefGoogle Scholar
  26. 26.
    Nichol KL, Wuorenma RN, von Sternberg T. Benefits of influenza vaccination for low-, intermediate-, and high-risk senior citizens. Arch Intern Med 1998; 158: 1769–76PubMedCrossRefGoogle Scholar
  27. 27.
    Hak E, van Essen GA, Buskens E, et al. Is immunising all patients with chronic lung disease in the community against influenza cost effective? Evidence from a general practice-based clinical prospective cohort study in Utrecht, The Netherlands. J Epidemiol Commun Health 1998; 52: 120–25CrossRefGoogle Scholar
  28. 28.
    Postma MJ, Bos JM, van Gennep M, et al. Economic evaluation of influenza vaccination; assessment for the Netherlands. Pharmacoeconomics 1999; 16Suppl. 1: 33–40PubMedCrossRefGoogle Scholar
  29. 29.
    Office of Technology Assessment. Cost effectiveness of influenza vaccination. Washington, DC: Office of Technology Assessment, 1981Google Scholar
  30. 30.
    Perez-Tirse J, Gross PA. Review of cost-benefit analyses of influenza vaccine. Pharmacoeconomics 1992; 2: 198–206PubMedCrossRefGoogle Scholar
  31. 31.
    Barker WH, Mullooly JP. Influenza vaccination of elderly persons: reduction in pneumonia and influenza hospitalisations and deaths. JAMA 1980; 244: 2547–49PubMedCrossRefGoogle Scholar
  32. 32.
    Schoenbaum SC. Economic impact of influenza: the individual’s perspective. Am J Med 1987; 82Suppl. 6A: 26–30PubMedCrossRefGoogle Scholar
  33. 33.
    Anderson RM, May RM. Vaccination and herd immunity to infectious diseases. Nature 1985; 318: 323–9PubMedCrossRefGoogle Scholar
  34. 34.
    Orenstein WA, Ferrara CP, Spraver MA, et al. Pharmacists’ role in immunization. Am J Hosp Pharm 1990; 47: 1273–4PubMedGoogle Scholar
  35. 35.
    Grabenstein JD, Hartzema AG, Guess HA, et al. Community pharmacists as immunisation advocates: a pharmacoepidemiologic `experiment. Int J Pharm Pract 1993; 2: 5–10CrossRefGoogle Scholar
  36. 36.
    Nichol KL, Margolis KL, Wuorenma J, et al. The efficacy and cost effectiveness of vaccination against influenza among elderly persons living in the community. N Engl J Med 1994; 331: 778–84PubMedCrossRefGoogle Scholar
  37. 37.
    Nichol KL, Goodman M. The health and economic benefits of influenza vaccination for healthy and at-risk persons aged 65 to 74 Years. Pharmacoeconomics 1999; 16Suppl. 1: 63–71PubMedCrossRefGoogle Scholar
  38. 38.
    Postma MJ, Reinders A, Jager JC, et al. Cost-effectiveness analysis of influenza vaccination in the Netherlands. Annual report 1996. Bilthoven: National Institute of Public Health and the Environment, 1997Google Scholar
  39. 39.
    Postma MJ, Jager JC, Reinders A, et al. Policy options and scenarios for influenza vaccination in The Netherlands. J Eur Sci Work Group Influenza 1997; 7: 5–6Google Scholar
  40. 40.
    Baltussen R, Reinders A, Sprenger MJW, et al. Estimating influenza-related hospitalizations in The Netherlands. Epidemiol Infect 1998; 121: 129–38PubMedCrossRefGoogle Scholar
  41. 41.
    Fiebach N, Beckett W. Prevention of respiratory infections in adults: influenza and pneumococcal vaccines. Arch Intern Med 1994; 154: 2545–57PubMedCrossRefGoogle Scholar
  42. 42.
    Margolis KL, Nichol KL, Poland GA, et al. Frequency of adverse reactions to influenza vaccination in the elderly: a randomized placebo-controlled trial. JAMA 1991; 91: 393–400Google Scholar
  43. 43.
    Schonberger LB, Bregman DJ, Sullivan-Bolyai JZ, et al. Guillain-Barré syndrome following vaccination in the National Influenza Immunization Program, United States, 1976–1977. Am J Epidemiol 1979; 110: 105–23PubMedGoogle Scholar
  44. 44.
    Kurland LT, Widerhold WC, Kirkpatrick JW, et al. Swine influenza vaccine and Guillain-Barré syndrome: epidemic or artefact? Arch Neurol 1985; 42: 1090–2CrossRefGoogle Scholar
  45. 45.
    Centers for Disease Control. Prevention and control of influenza: part I. Vaccines: recommendations of the Advisory Committe on Immunization Practices. MMWR Morb Mortal Wkly Rep 1993; 42: 1–14Google Scholar
  46. 46.
    Baltussen RMPM. Real World Designs in Economic Evaluation: bridging the gap between clinical research and policy making [thesis]. Maastricht: Maastricht University, 1998Google Scholar
  47. 47.
    Govaert ThME, Thijs CTMCN, Masurel N, et al. The efficacy of influenza vaccination in elderly individuals: a randomized double-blind placebo-controlled trial. JAMA 1994; 272: 1661–5PubMedCrossRefGoogle Scholar
  48. 48.
    Gross PA, Hermogenes AW, Sacks HS, et al. The efficacy of influenza vaccine in elderly persons: a meta-analysis and review of the literature. Ann Intern Med 1995; 123: 518–27PubMedGoogle Scholar
  49. 49.
    Fedson DS, Wajda A, Nicol JP, et al. Clinical effectiveness of influenza vaccination in Manitoba. JAMA 1993; 270: 1956–61PubMedCrossRefGoogle Scholar
  50. 50.
    Foster DA, Talsma A, Furumoto-Dawson A, et al. Influenza vaccine effectiveness in preventing hospitalization for pneumonia in the elderly. Am J Epidemiol 1992; 136: 296–307PubMedGoogle Scholar
  51. 51.
    Ohmit SE, Monto AS. Influenza vaccine effectiveness in preventing hospitalization among the elderly during influenza type A and type B seasons. Int J Epidemiol 1995; 24: 1240–8PubMedCrossRefGoogle Scholar
  52. 52.
    Postma MJ, Jager JC, Reinders AR, et al. Standards for cost-effectiveness analysis; a Dutch study on influenza vaccination. Health Syst Sci 1997; 1: 413–24Google Scholar
  53. 53.
    Patriarca PA, Weber JA, Parker RA, et al. Efficacy of influenza vaccine in nursing homes: reduction in illnesses and complications during an influenza A (H3N2) epidemic. JAMA 1985; 253: 1136–9PubMedCrossRefGoogle Scholar
  54. 54.
    Centers for Disease Control. Prevention and control of influenza. JAMA 1988; 260: 318–22CrossRefGoogle Scholar
  55. 55.
    Ruben FL. Prevention of influenza in the elderly. J Am Geriatr Soc 1982; 30: 577–80PubMedGoogle Scholar
  56. 56.
    Centers for Disease Control. Public health burden of vaccine-preventable diseases among adults: standards for adult immunization practice. MMWR Morb Mortal Wkly Rep 1990; 39: 725–9Google Scholar
  57. 57.
    Lombaert G, DeGraeve D, Goossens H. An evaluation of pneumococcal vaccination for Belgium [in Dutch]. Antwerp: University of Antwerp, 1997. Report no: 97/342Google Scholar
  58. 58.
    Laupacis A, Feeny D, Detsky AS, et al. How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. Can Med Assoc J 1992; 146: 473–81Google Scholar
  59. 59.
    Owens DK. Interpretation of cost-effectiveness analyses. J Gen Intern Med 1998; 13:716–7PubMedCrossRefGoogle Scholar
  60. 60.
    Jefferson T, Mugford M, Gray A, et al. An exercise on the feasibility of carrying out secondary economic analyses. Health Econ 1996; 5: 155–65PubMedCrossRefGoogle Scholar
  61. 61.
    Weinstein MC, Stason WB. Foundations for cost-effectiveness analysis for health and medical practices. N Engl J Med 1977; 296:716–21PubMedCrossRefGoogle Scholar
  62. 62.
    Russel LB. Is prevention better than cure? Washington, DC: Brookings Institution, 1986Google Scholar
  63. 63.
    Gold MR, Siegel JE, Russel LB, et al. Cost-effectiveness in health and medicine. New York: Oxford University Press, 1996Google Scholar
  64. 64.
    Polder JJ, Meerding WJ, Koopmanschap M, et al. Costs of diseases in The Netherlands 1994 [in Dutch]. Rotterdam: Erasmus University, 1997. Report no: MGZ. 97.27Google Scholar
  65. 65.
    Postma MJ, Jager JC, Ruwaard D, et al. Disease-staging for modelling current and future health-care impact of disease; illustrations for diabetes mellitus and AIDS. Health Policy 1998; 43: 45–54PubMedCrossRefGoogle Scholar
  66. 66.
    Gardner JW, Sanborn JS. Years of potential life lost (YPLL): what does it measure? Epidemiology 1990; 1: 322–9PubMedCrossRefGoogle Scholar
  67. 67.
    Tengs TO. Enormous variation in the cost-effectiveness of prevention: implications for public policy. Curr Issues Public Health 1996; 2: 13–7Google Scholar
  68. 68.
    Drummond MF, Brandt A, Luce B, et al. Standardizing methodologies for economic evaluation in health care; practice, problems and potential. Int J Technol Assess Health Care 1993; 1: 26–36CrossRefGoogle Scholar
  69. 69.
    Drummond MF, Torrance GW, Mason J. Cost-effectiveness league tables: more harm than good? Soc Sci Med 1993; 1: 33–40CrossRefGoogle Scholar
  70. 70.
    Parsonage M, Neuburger H. Discounting and health benefits. Health Econ 1992; 1:71–6PubMedCrossRefGoogle Scholar
  71. 71.
    Cairns J. Discounting and health benefits: another perspective. Health Econ 1992; 1:76–9PubMedCrossRefGoogle Scholar
  72. 72.
    Baltussen R, Leidl R, Ament A. The impact of age on cost-effectiveness ratios and its control in decision-making. Health Econ 1996; 5: 227–39PubMedCrossRefGoogle Scholar
  73. 73.
    Osterhaus A, de Jong J. The battle against influenza: antivirals versus vaccines. J Eur Sci Work Group Influenza 1999; 10: 6Google Scholar
  74. 74.
    Meltzer MI, Cox NJ, Fukuda K. The economic impact of pandemic influenza in the United States: priorities for intervention. Emerg Infect Dis 1999; 5: 659–71PubMedCrossRefGoogle Scholar
  75. 75.
    Tengs TO, Adams ME, Pliskin JS, et al. Five hundred life-saving interventions and their cost-effectiveness. Risk Analysis 1995; 15: 369–90PubMedCrossRefGoogle Scholar
  76. 76.
    Postma MJ, Heijnen MLA, Jager JC. Cost-effectiveness of pneumococcal vaccination for Dutch elderly. Pharmacoeconomics. In pressGoogle Scholar

Copyright information

© Adis International Limited 2000

Authors and Affiliations

  • Maarten J. Postma
    • 1
  • Rob M. P. M. Baltussen
    • 2
  • Marie-Louise A. Heijnen
    • 3
  • Lolkje T. W. de Jong-van den Berg
    • 1
  • Johannes C. Jager
    • 3
  1. 1.Groningen University Institute for Drug Exploration/Groningen Research Institute of Pharmacy (GUIDE/GRIP)GroningenThe Netherlands
  2. 2.Department of Tropical Hygiene and Public HealthHeidelberg UniversityHeidelbergGermany
  3. 3.National Institute of Public Health and the EnvironmentBilthovenThe Netherlands

Personalised recommendations